NewsRoom Articles - Page 74 of 154 - PsychedelicNewsWire (PNW)

TuesdayJan 04, 2022 2:48 pm

Study Finds That Psilocybin’s Therapeutic Effect Isn’t Altered by SSRI Medication

Compass Pathways recently released data that shows that selective serotonin reuptake inhibitor (“SSRI”) drugs can be used together with psilocybin. SSRI drugs are commonly used to treat mental health conditions including anxiety and depression. Estimates show that more than 300 million individuals globally suffer from major depressive disorder, with about one-third of that population not getting finding any help or relief from current therapies. Compass is carrying out a trial for its COMP360 psilocybin formulation, which involves patients on SSRI therapy being administered with one 25 mg dose of its therapeutic formulation. The study found that the treatment outcomes in…

TuesdayJan 04, 2022 10:39 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Milestone Notice of Allowance for Revolutionary Treatment of Anxiety Disorders

USPTO notice marks important milestone in the expansion of CYBN’s intellectual property portfolio Once issued, patent may have opportunity to cover a broad range of claims Anxiety disorders are one of the most common mental illnesses in the United States Cybin (NEO: CYBN) (NYSE American: CYBN) has taken another step forward in its commitment to progressing Psychedelics to Therapeutics(TM). The biopharmaceutical company has received a notice of allowance from the U.S. Patent and Trademark Office (“USPTO”) in regard to its patent application connected to its investigational deuterated psychedelic tryptamine compound for the potential treatment of anxiety disorders (https://ibn.fm/fpjXm). “The receipt of…

MondayJan 03, 2022 1:20 pm

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) CEO Joins Gamechangers LIVE Podcast; Shares Views on the Evolution of the Psychedelics Industry

Delic Corp is a leading psychedelic wellness platform with a business network which includes psychedelic wellness clinics, psilocybin research facilities, a famed psychedelic wellness event, and dedicated media and e-commerce platforms Delic’s CEO, Matt Stang recently joined the Gamechangers LIVE podcast to share his perspective on the development of the psychedelic industry along with Delic’s commercial evolution Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leading psychedelic wellness platform committed to bringing science-backed benefits to its many stakeholders, has long been known for its role as a trailblazer of new medicines and treatments in the current environment. Its goal is to…

ThursdayDec 30, 2021 3:45 pm

Washington City Approves Measure to Decriminalize Psychedelic Substances

Last week, the city of Port Townsend became the latest city to decriminalize entheogenic fungi and plants through a measure that was unanimously adopted by the city council of Port Townsend. This Washington State city is the latest city to relax its policy on psychedelic substances. Under the approved measure, laws against natural psychedelic plants including ayahuasca, peyote and magic mushrooms, will be the lowest priority for law enforcement in the city. Natural psychedelic substances are sometimes referred to as entheogenic fungi and plants. The initiative also conveys support for the decriminalization of psychedelic drugs at the federal level. In…

ThursdayDec 30, 2021 1:19 pm

Psychedelics May Be Key to Effective Dementia Treatment

Dementia is known to affect an individual’s mental processes, leading to loss of cognitive functioning. It is typically caused by brain injury or disease and is marked by impaired reasoning, changes in personality and memory disorders. In its later stages, the disease kills off the brain cells linked to muscle control, gradually limiting the person’s ability to stand, walk and even swallow food. Estimates from the CDC show that more than 5.7 million individuals suffer from dementia and Alzheimer’s disease, a progressive disorder that destroys memory. Projections show that this number could reach roughly 14 million in the next four…

WednesdayDec 29, 2021 12:33 pm

Congressman Calls on Colleagues to Urge DEA to Permit Psilocybin Access

Rep. Earl Blumenauer is asking fellow legislators to join him in urging the DEA to permit patients suffering from terminal illnesses to use psilocybin as part of their treatment, without fear of being federally prosecuted. In a letter circulated by Blumenauer, he notes that there are federal as well as state right-to-try legislations that should allow particular patients to access the psychedelic as an investigational treatment. Blumenauer states in the letter that there existed a growing body of evidence pointing to the effectiveness and safety of psilocybin-assisted therapy as a possible way to provide care to people with anxiety and/or…

WednesdayDec 29, 2021 11:41 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) to Open 2 New Ketamine Infusion Clinics; Co-Founder and CEO Matt Stang Reveals Investor Relations Efforts

Delic Holdings subsidiary, Ketamine Wellness Centers, announced plans to open two new clinics in the coming weeks The clinics, to be located in Salt Lake City, Utah and Reno, Nevada will take KWC’s total clinic count to 14, forming part of the company’s plan to open 13 new ketamine infusion clinics across the country over the next 18 months Following Delic’s keynote ‘Meet Delic’ conference on Nov. 6-7, CEO Matt Stang announced plans to attend the upcoming HC Wainwright Bioconnect Virtual Conference as well as CEM’s 8th annual AlphaNorth Capital Conference in January 2022 Delic Holdings (CSE: DELC) (OTCQB: DELCF),…

TuesdayDec 28, 2021 2:17 pm

New Trial to Test Psilocybin Effectiveness in Treating Depressed Healthcare Workers

Researchers from the School of Medicine at the University of Washington are conducting a clinical trial to treat depressed medical professionals using psychedelics. This comes at a time when healthcare professionals in the United States are seeking ways to deal with the emotional and mental anguish brought on by the coronavirus pandemic. A survey conducted last year that involved more than 20,000 health care workers found that 49% suffered from burnout as a result of the pandemic while another 38% revealed that they had experienced depression or anxiety. Another report from Morning Consult has also highlighted that more than one-half…

MondayDec 27, 2021 2:20 pm

Colorado Activists File Measures to Legalize Psychedelic Substances

Voters in the state of Colorado may get the chance to vote to legalize the growing and possession of psychedelic substances next year, as well as establish a system of licensed businesses to produce psychedelics such as ibogaine, DMT and psilocybin to be used at healing centers. This comes after New Approach PAC filed a pair of psychedelic reform measures for the state’s 2022 ballot with the secretary of state’s office. New Approach PAC is a national advocacy group that is behind the medical psilocybin legalization measure that voters in Oregon passed in 2020, as well as a couple of…

ThursdayDec 23, 2021 1:53 pm

Study Links Ayahuasca’s Ceremonial Use to Decline in Neuroticism

A new study has found evidence suggesting that the use of ayahuasca in ceremonies can cause a substantial decrease in neuroticism. Neuroticism is a personality trait that has been linked to anxiety and depression. Ayahuasca, on the other hand, is a brew that has been used by the indigenous peoples of the Amazonian basin and Brazil for centuries. It contains monoamine oxidase inhibitors and DMT, a potent psychedelic substance. Prior studies have discovered evidence proposing that the consumption of ayahuasca has psychological benefits. Brandon Weiss, an Imperial College London research associate and author of the new study, stated that the…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000